Malaria vaccines: the stage we are at. (Q47835806)

6 February 2018

title

Malaria vaccines: the stage we are at. (English)

1 reference

6 February 2018

0 references

1 reference

2

Adrian V S Hill

1 reference

6 February 2018

Stephen M Todryk

1

1 reference

6 February 2018

language of work or name

English

0 references

publication date

1 July 2007

1 reference

6 February 2018

Nature Reviews Microbiology

published in

1 reference

6 February 2018

volume

5

1 reference

6 February 2018

issue

7

1 reference

6 February 2018

page(s)

487-489

1 reference

6 February 2018

Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

The malaria Atlas Project: developing global maps of malaria risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Pre-erythrocytic malaria vaccines: towards greater efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Viral vectors for malaria vaccine development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1712

31 March 2020

Identifiers

DOI

10.1038/NRMICRO1712

1 reference

6 February 2018

1 reference

6 February 2018